NCI Genomic Characterization Centers

The National Cancer Institute (NCI) Genomic Characterization Centers Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle provides comprehensive genomic characterization services across DNA, RNA, and protein analysis domains. The master contract enables the Center for Cancer Genomics (CCG) to acquire high-resolution, systematic, genome-wide characterization of cancer-related genomic alterations through multiple prime contractors. The objective is to support genomic research by developing, implementing, and maintaining rigorous standards across the entire genomic characterization pipeline, with a focus on minimizing study variables and ensuring robust quality assurance and quality control.

Task orders under this IDIQ consistently demonstrate firm fixed-price delivery mechanisms, typically ranging from $190,000 to $19.7 million, with performance periods spanning 1-5 years. Prime contractors frequently include academic research institutions such as The Broad Institute, University of North Carolina at Chapel Hill, New York Genome Center, and Genewiz, LLC. The National Cancer Institute funds these task orders, which uniformly lack specific small business set-aside designations. Genomic services covered include whole genome sequencing, whole exome sequencing, RNA sequencing, DNA methylation arrays, and single-cell sequencing, with performance primarily occurring at contractors' research facilities. Most task orders support specific research initiatives like the Cancer Genome Characterization Initiative, Clinical Proteomic Tumor Analysis Consortium, and Division of Cancer Epidemiology and Genetics.